Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Rinnerthaler Gabriel |
Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen
Breitenstein, U; Wrobel, D; Guth, D; Zaiss, M; Terhaag, J; Zahn, MO; Perlova-Griff, L; Distelrath, A; Wuerstlein, R; Apel, K; Deuerling, N; Vannier, C; Bartsch, R; Jackisch, C; Mueller, V; Schmidt, M; Balic, M; Rinnerthaler, G; Lueftner, D; Zaman, K; Schwitter, M; Harbeck, N
Extended adjuvant (adj) neratinib in HER2+/HR+ early breast cancer (eBC) in clinical routine - interim analysis of the multinational, prospective, non-interventional study (NIS) ELEANOR (n=300)
BREAST. 2025; 80: 103911
Doi: 10.1016/j.breast.2025.103911
Web of Science
FullText
FullText_MUG
Dobri, N; Dandachi, N; Klocker, EV; Suppan, C; Graf, R; Lazzeri, I; Albertini, C; Rinnerthaler, G; Starzer, AM; Bartsch, R; Hasenleithner, SO; Jost, PJ; Heitzer, E; Balic, M
Circulating tumor DNA profiling of patients with metastatic luminal HER2-low and HER2-0 breast cancer via next-generation sequencing.
J CLIN ONCOL. 2025; 43(16_SUPPL): e13090-e13090.
Doi: 10.1200/JCO.2025.43.16_suppl.e13090
Web of Science
FullText
FullText_MUG
Beheshti, M; Rinnerthaler, G; Farbod, A; Hitzl, W; Egle, D; Gampenrieder, SP; Bartsch, R; Balic, M; Greil, R; Gnant, M; Pirich, C
Predictive role of baseline [18F]FDG PET/CT quantitative parameters for response to neoadjuvant treatment with atezolizumab, trastuzumab, pertuzumab and epirubicin in HER2-positive early breast cancer - a substudy of the ABCSG-52/ATHENE phase II trial
EUR J NUCL MED MOL I. 2024; 51: S481-S482.
[Poster]
Web of Science